SERETIDE ACCUHALER 50250MCG

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

FLUTICASONE PROPIONATE; SALMETEROL XINOFOATE

Boleh didapati daripada:

GLAXOSMITHKLINE PHARMACEUTICAL SDN. BHD.

INN (Nama Antarabangsa):

FLUTICASONE PROPIONATE; SALMETEROL XINOFOATE

Unit dalam pakej:

1Units Units

Dikeluarkan oleh:

GLAXO WELLCOME PRODUCTION

Risalah maklumat

_Consumer Medication Information Leaflet (RiMUP)_
_ _
1
SERETIDE ACCUHALER
Salmeterol xinofoate/ Fluticasone propionate (50/100, 50/250, 50/500
micrograms)
WHAT IS IN THIS LEAFLET
1.
What SERETIDE is used for
2.
How SERETIDE works
3.
Before you use SERETIDE
4.
How to use SERETIDE
5.
While you are using it
6.
Side Effects
7.
Storage and Disposal of
SERETIDE
8.
Product Description
9.
Manufacturer and Product
Registration Holder
10.
Date of Revision
WHAT SERETIDE IS USED FOR
Your doctor has chosen this
medicine to suit you and your
condition. SERETIDE is used to
help with breathing problems in
people who need regular
treatment.
Asthma is a long-term condition
affecting the lungs. Symptoms
of asthma include shortness of
breath, wheezing, chest tightness
and cough. Two main causes of
asthma symptoms are
bronchoconstriction (tightening
of the muscle surrounding the
airways) and inflammation
(swelling and irritation of the
airways).
Chronic obstructive pulmonary
disease (COPD) is a long-term,
progressively worsening
condition affecting the lungs,
resulting from chronic bronchitis
or emphysema (linings of the air
sacs in the lungs damaged
beyond repair). Symptoms of
COPD include shortness of
breath, cough, chest discomfort
and coughing up mucus. The
primary cause of COPD
symptoms are
bronchoconstriction (tightening
of the muscle surrounding the
airways) and inflammation
(swelling and irritation of the
airways). SERETIDE Accuhaler,
at a dose of 50/500 micrograms,
has been shown to increase
survival and reduce the number
of flare ups of COPD symptoms.
HOW SERETIDE WORKS
Salmeterol xinafoate is one of a
group of medicines called
bronchodilators. It relaxes the
muscles in the walls of the small
air passages in the lungs. This
helps to open the airways and
makes it easier for air to get in
and out of the lungs. The effects
of salmeterol xinafoate last for at
least 12 hours. When it is taken
regularly it helps the small air
passages to remain open.
Fluticasone propionate is one of
a group of medicines called
corticosteroids wh

Ciri produk

CONFIDENTIAL
[GSK logo]
SERETIDE ACCUHALER
Salmeterol/fluticasone propionate
QUALITATIVE AND QUANTITATIVE COMPOSITION
Moulded plastic device containing a foil strip with 60 regularly
placed blisters each
containing 50 micrograms of salmeterol as salmeterol xinafoate and 100
micrograms of
fluticasone propionate.
Moulded plastic device containing a foil strip with 60 regularly
placed blisters each
containing 50 micrograms of salmeterol as salmeterol xinafoate and 250
micrograms of
fluticasone propionate.
Moulded plastic device containing a foil strip with 60 regularly
placed blisters each
containing 50 micrograms of salmeterol as salmeterol xinafoate and 500
micrograms of
fluticasone propionate.
CLINICAL INFORMATION
Pharmaceutical form: Inhalation powder.
INDICATIONS
ASTHMA
_SERETIDE _
is indicated in the regular treatment of asthma, including asthma in
children
and adults, where use of a combination (bronchodilator and inhaled
corticosteroid) is
appropriate.
This may include:
Patients on effective maintenance doses of long-acting beta-agonists
and inhaled
corticosteroids.
Patients who are symptomatic on current inhaled corticosteroid
therapy.
Patients on regular bronchodilator therapy who require inhaled
corticosteroids.
CONFIDENTIAL
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
_SERETIDE _
is indicated for the regular treatment of chronic obstructive
pulmonary
disease (COPD) including chronic bronchitis and emphysema.
DOSAGE AND ADMINISTRATION
_SERETIDE _
Accuhaler is for inhalation only.
Patients should be made aware that
_SERETIDE _
Accuhaler must be used regularly for
optimum benefit, even when asymptomatic.
Patients should be regularly reassessed by a doctor, so that the
strength of
_SERETIDE _
they are receiving remains optimal and is only changed on medical
advice.
ASTHMA
The dose should be titrated to the lowest dose at which effective
control of symptoms is
maintained. Where the control of symptoms is maintained with twice
daily
_SERETIDE_
,
titration to the lowest effective dose could include
_SERETIDE _